Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BARACK-D trial of spironolactone in chronic kidney disease
ISRCTN44522369Phase 3Completed
- Sponsor
- University of Oxford
- Start
- Dec 2013
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of spironolactone in chronic kidney disease (CKD) (2 arms), sponsored by University of Oxford. Primary endpoints: Effect of aldosterone receptor antagonism on mortality and cardiovascular outcomes and Long-term mortality and cardiovascular outcomes. Started Dec 2013; status: completed.
02
Drugs
spironolactone
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on ISRCTN44522369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN44522369.